看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。* {( S0 q/ |, I
' A$ v$ _0 h5 B) q( L. s
) I1 |' Z4 ^- h3 K+ Q# ]( c
Currently available feasibility data for possible combination strategies. 7 ? U9 a' z# n! R3 F: ^
————————————————————————————————" b# g5 n8 U1 B8 V6 k! h5 k
Combination Feasibility according to preliminary data
. Q! l4 M& p* G- ^——————————————————————————————————' i9 a1 _: e( s! F' b8 s* G
Bevacizumab + sorafenib Yes, reduced dose 4 U5 B8 R l( d5 J7 Y( W
Bevacizumab + sunitinib† No
! `- i; O5 P4 r4 {1 l5 lBevacizumab + temsirolimus Yes - {& X3 D7 y0 Z1 Y9 I
Bevacizumab + everolimus Yes `! f5 m8 J& Y6 [ |% j
Sorafenib + sunitinib ? % H+ Z: Y5 e! |) m' f
Sorafenib + temsirolimus Yes, reduced dose / D. n& y( p: W# W( j7 {5 e
Sorafenib + everolimus Yes, reduced dose
- U6 B: e% w9 c K( w. dSunitinib + temsirolimus† No
) x; {5 d. f: [$ O: T/ {Sunitinib + everolimus ?
7 D$ w0 j4 L/ f6 WTemsirolimus + everolimus ? : B, @6 D+ `. {0 E
————————————————————
4 ?# T, X2 e+ v" L) k7 p0 }†Led to US FDA warning.) b8 [6 j v& @6 y/ `" W
?: As yet unattempted combination.
8 ^' g! F- A- o. S3 D+ o' V6 {' h |